Reuters logo
BRIEF-Esperion announces initiation of pivotal late stage study for bempedoic acid
November 6, 2017 / 10:02 PM / a month ago

BRIEF-Esperion announces initiation of pivotal late stage study for bempedoic acid

Nov 6 (Reuters) - Esperion Therapeutics Inc

* Esperion announces initiation of pivotal late stage study for the bempedoic acid / ezetimibe combination pill

* Esperion Therapeutics - ‍NDA submission for LDL-C lowering indication for bempedoic acid / ezetimibe combination pill expected by Q1 2019​

* Esperion Therapeutics Inc - ‍top-line results expected by q4 of 2018 for bempedoic acid / ezetimibe combination pill​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below